Literature DB >> 21742792

Factor XIII: a coagulation factor with multiple plasmatic and cellular functions.

László Muszbek1, Zsuzsanna Bereczky, Zsuzsa Bagoly, István Komáromi, Éva Katona.   

Abstract

Factor XIII (FXIII) is unique among clotting factors for a number of reasons: 1) it is a protransglutaminase, which becomes activated in the last stage of coagulation; 2) it works on an insoluble substrate; 3) its potentially active subunit is also present in the cytoplasm of platelets, monocytes, monocyte-derived macrophages, dendritic cells, chondrocytes, osteoblasts, and osteocytes; and 4) in addition to its contribution to hemostasis, it has multiple extra- and intracellular functions. This review gives a general overview on the structure and activation of FXIII as well as on the biochemical function and downregulation of activated FXIII with emphasis on new developments in the last decade. New aspects of the traditional functions of FXIII, stabilization of fibrin clot, and protection of fibrin against fibrinolysis are summarized. The role of FXIII in maintaining pregnancy, its contribution to the wound healing process, and its proangiogenic function are reviewed in details. Special attention is given to new, less explored, but promising fields of FXIII research that include inhibition of vascular permeability, cardioprotection, and its role in cartilage and bone development. FXIII is also considered as an intracellular enzyme; a separate section is devoted to its intracellular activation, intracellular action, and involvement in platelet, monocyte/macrophage, and dendritic cell functions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21742792     DOI: 10.1152/physrev.00016.2010

Source DB:  PubMed          Journal:  Physiol Rev        ISSN: 0031-9333            Impact factor:   37.312


  128 in total

1.  Coagulation factor XIIIa is inactivated by plasmin.

Authors:  Woosuk S Hur; Nima Mazinani; X J David Lu; Heidi M Britton; James R Byrnes; Alisa S Wolberg; Christian J Kastrup
Journal:  Blood       Date:  2015-09-10       Impact factor: 22.113

Review 2.  Immunopathology of chronic rhinosinusitis.

Authors:  Atsushi Kato
Journal:  Allergol Int       Date:  2015-02-09       Impact factor: 5.836

3.  Identification of a FXIIIA variant in human neuroblastoma cell lines.

Authors:  Martina lannaccone; Gaia Giuberti; Giulia De Vivo; Michele Caraglia; Vittorio Gentile
Journal:  Int J Biochem Mol Biol       Date:  2013-07-29

4.  Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.

Authors:  J D Beckman; L A Holle; A S Wolberg
Journal:  J Thromb Haemost       Date:  2017-11-20       Impact factor: 5.824

5.  Coagulation factor XIIIa cross-links amyloid β into dimers and oligomers and to blood proteins.

Authors:  Woosuk S Hur; Nima Mazinani; X J David Lu; Leeor S Yefet; James R Byrnes; Laura Ho; Ju Hun Yeon; Sam Filipenko; Alisa S Wolberg; Wilfred A Jefferies; Christian J Kastrup
Journal:  J Biol Chem       Date:  2018-11-08       Impact factor: 5.157

6.  Evaluating the Effects of Fibrinogen αC Mutations on the Ability of Factor XIII to Crosslink the Reactive αC Glutamines (Q237, Q328, Q366).

Authors:  Kelly Njine Mouapi; Lucille J Wagner; Chad A Stephens; Mohammed M Hindi; Daniel W Wilkey; Michael L Merchant; Muriel C Maurer
Journal:  Thromb Haemost       Date:  2019-05-05       Impact factor: 5.249

Review 7.  Vein graft failure.

Authors:  Christopher D Owens; Warren J Gasper; Amreen S Rahman; Michael S Conte
Journal:  J Vasc Surg       Date:  2013-10-03       Impact factor: 4.268

8.  The interaction between fibrinogen and zymogen FXIII-A2B2 is mediated by fibrinogen residues γ390-396 and the FXIII-B subunits.

Authors:  James R Byrnes; Clare Wilson; Anthony M Boutelle; Chase B Brandner; Matthew J Flick; Helen Philippou; Alisa S Wolberg
Journal:  Blood       Date:  2016-08-25       Impact factor: 22.113

Review 9.  [Factor XIII : Pharmacodynamic and pharmacokinetic characteristics].

Authors:  E H Adam; S Kreuer; K Zacharowski; C F Weber; R Wildenauer
Journal:  Anaesthesist       Date:  2017-01       Impact factor: 1.041

10.  Monocyte-directed RNAi targeting CCR2 improves infarct healing in atherosclerosis-prone mice.

Authors:  Maulik D Majmudar; Edmund J Keliher; Timo Heidt; Florian Leuschner; Jessica Truelove; Brena F Sena; Rostic Gorbatov; Yoshiko Iwamoto; Partha Dutta; Gregory Wojtkiewicz; Gabriel Courties; Matt Sebas; Anna Borodovsky; Kevin Fitzgerald; Marc W Nolte; Gerhard Dickneite; John W Chen; Daniel G Anderson; Filip K Swirski; Ralph Weissleder; Matthias Nahrendorf
Journal:  Circulation       Date:  2013-04-24       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.